Clinical trial
A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of BMS-986511 in Two Sequential Parts in Participants With Major Depressive Disorder
NCT07772531 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of BMS-986511 in Two Sequential Parts in Participants With Major Depressive Disorder
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 30, 2026
- Completion date
- November 6, 2028
- Enrollment
- 200 (estimated)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.